Another recent study showed that NRF2 activation in cancer cells by either KEAP1 mutation or pharmacological stimulation leads to decreased intracellular glutamate pools at least partly through SLC7A11-mediated glutamate export, resulting in enhanced sensitivity to glutamine starvation and glutaminase inhibition [58]. Here, SLC7A11 is linked to cancer.